Key Findings
- High CXCL9/10 expression was associated with an immune-active tumor microenvironment and improved overall survival
following pembrolizumab, independent of PD-L1 and TMB, in a large cohort of TNBCs profiled by Caris. - This study demonstrates how integrated genomic, transcriptomic, and immune profiling can identify
biologically distinct breast cancer subgroups, refine therapeutic stratification, and uncover potential biomarkers of
treatment response and resistance across metastatic, hormone receptor–positive, and triple-negative disease.